What We Learned After 5,000 Nonsurgical Rhinoplasties
For selected patients, this dermal filler technique offers a quick, safe way to reshape the nose, reports a study in Plastic and Reconstructive Surgery
As patients continue to seek noninvasive treatments across the cosmetic spectrum, "liquid rhinoplasty" is emerging as the nonsurgical alternative to the traditional nose job. Using dermal fillers to change the appearance of the nose, nonsurgical rhinoplasty is gaining in popularity due to its relatively low cost, convenience and short recovery time.
There has previously been debate regarding the safety and effectiveness of this procedure – especially in the absence of large-scale studies reporting on the patient outcomes. To address this gap, the March issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS), features a new study that includes an analysis of 5,000 nonsurgical rhinoplasties performed between 2015 and 2019 – the largest published experience of nonsurgical rhinoplasty to date.
The study's lead author, Ayad Harb, FRCSPlast, is a London Consultant Plastic Surgeon and world authority on this increasingly popular procedure. "We find this treatment an excellent alternative to surgical rhinoplasty in those patients who do not want, cannot have, or do not need surgery," writes Dr. Harb. "This study demonstrates high efficacy and safety, and relatively low complication rates in the hands of an experienced clinician."
The study outlines a safe and effective nonsurgical rhinoplasty technique, which focuses on three critical aesthetic points of the nose—the radix, bridge and tip.
"The injections are carried out at the radix and move caudally with a micro-droplet technique. Boluses of no more than 0.1 mL at any one point," writes Dr. Harb. "Frequently, and especially nearer the tip, deposits of filler can be as small as 0.02 mL per site. With each injection point, the gel implant is massaged into place and can be maneuverer to produce a smooth and symmetrical surface. The injections continue in the midline until the tip is reached. The tip is injected perpendicular to the skin to improve projection and definition."
According to the study, hyaluronic acid is the preferred filler because of its reversibility in the event of vascular occlusion. Another benefit is that it can be pre-mixed with local anaesthetic, avoiding the requirement for pre-procedural local anaesthetic which can distort or mask subtle deformities that one is looking to correct.
The patients' mean age was 27 years old (range 18 – 78), and the largest age group was 25-34 years, totalling 52% of the cohort, with a female predominance in the cohort. The average procedure time was just 12 minutes, while the average of filler injected was less than one millilitre (0.72 mL), and the average pain score was only 2 on a 10-point scale.
The most common patient complaint was a dorsal hump, affecting 44 percent. About 20 percent of patients were seeking to refine their results after previous rhinoplasty surgery. Liquid rhinoplasty was also used to treat other patient concerns, such as drooping nasal tip (about 15 percent), lack of definition (almost nine percent), frontal asymmetry (seven percent) and bulbous tip (six percent).
"Practitioners who undertake nonsurgical rhinoplasty must have a comprehensive understanding of nasal anatomy and aesthetics. It is also vital to maintain an acute ability to recognise immediate complications and a readiness to treat," wrote Dr. Harb. "This study demonstrates low complication rates, with an infection and skin necrosis rate of 0.04 and 0.06 percent, respectively."
Erythema and swelling were a common observation in the first five days, but generally settle with time. Other complications were infrequent. A small number of patients (0.5 percent) showed signs of vascular occlusion; in most cases, blood flow was restored with simple measures. If not, a hyaluronidase enzyme injection was performed to immediately dissolve the dermal filler.
The duration of results was 9 to 12 months. Approximately 32 percent of patients returned at 12 months, most of whom were treated. Many patients demonstrate long-lasting results, some not requiring further treatment even at 24-month follow up.
Click here to read "The Nonsurgical Rhinoplasty: A Retrospective Review of 5000 Treatments"
Article: "The Nonsurgical Rhinoplasty: A Retrospective Review of 5000 Treatments" (doi: 10.1097/PRS.0000000000006554)
About Plastic and Reconstructive Surgery
For more than 70 years, Plastic and Reconstructive Surgery® has been the one consistently excellent reference for every specialist who uses plastic surgery techniques or works in conjunction with a plastic surgeon. The official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery® brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues.
The American Society of Plastic Surgeons (ASPS) is the world's largest organization of board-certified plastic surgeons. Representing more than 8,000 member surgeons, the Society is recognized as a leading authority and information source on aesthetic and reconstructive plastic surgery. ASPS comprises more than 93 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the Society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada. ASPS advances quality care to plastic surgery patients by encouraging high standards of training, ethics, physician practice and research in plastic surgery.
About Wolters Kluwer
Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer reported 2015 annual revenues of €4.2 billion. The group serves customers in over 180 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and organization, visit www.wolterskluwer.com, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.